Tzu Chi Medical Journal
Volume 21, Issue 4 , Pages 277-284 , December 2009

Intravesical Botulinum Toxin Injection for Overactive Bladder—What We Can Learn From Previous Clinical Trials

  • Hann-Chorng Kuo

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Urology, Buddhist Tzu Chi General Hospital, 707, Section 3, Chung-Yang Road, Hualien, Taiwan

Received 22 September 2009 ,Revised 15 October 2009 ,Accepted 17 October 2009.

References 

  1. Abrams P , Kelleher CJ , Kerr LA , Rogers RG . Overactive bladder significantly affects quality of life . Am J Manag Care . 2000;6(Suppl 11):S580–S590
  2. Irwin DE , Milsom I , Kopp Z , Abrams P , Cardozo L . Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries . BJU Int . 2006;97:96–100
  3. Yoshimura N . Lower urinary tract symptoms (LUTS) and bladder afferent activity . Neurourol Urodyn . 2007;26(Suppl 6):908–913
  4. Chapple CR . Muscarinic receptor antagonist in the treatment of overactive bladder . Urology . 2000;55(Suppl 5A):33–50
  5. Dong M , Yeh F , Tepp WH , et al.   SV2 is the protein receptor for botulinum neurotoxin A . Science . 2006;312:592–596
  6. Dykstra DD , Sidi AA , Scott AB , Pagel JM , Goldish GD . Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients . J Urol . 1988;139:919–922
  7. Schurch B , Stohrer M , Kramer G , Schmid DM , Gaul G , Hauri D . Botulinum-A toxin for treating detrusor hyper-reflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results . J Urol . 2000;164:692–697
  8. Reitz A , Stohrer M , Kramer G , et al.   European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity . Eur Urol . 2004;45:510–515
  9. Aoki KR , Guyer B . Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions . Eur J Neurol . 2001;8(Suppl 5):21–29
  10. Apostolidis A , Popat R , Yiangou Y , et al.   Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of Botulinum toxin for human detrusor overactivity . J Urol . 2005;174:977–982
  11. Yiangou Y , Facer P , Ford A , et al.   Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder . BJU Int . 2001;87:774–779
  12. Avelino A , Cruz F . TRPVI (vanilloid receptor) in the urinary tract: expression, function and clinical applications . Naunyn Schmiedebergs Arch Pharmacol . 2006;373:287–299
  13. Aoki KR . Evidence for antinociceptive activity of botulinum toxin type A in pain management . Headache . 2003;43(Suppl 1):S9–15
  14. Cui M , Aoki KR . Botulinum toxin type A (BTX-A) reduces inflammatory pain in the rat formalin model . Cephalalgia . 2000;20:414–418
  15. Kuo HC . Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents . Urology . 2004;63:868–872
  16. Kessler TM , Danuser H , Schumacher M , Studer UE , Burkhard FC . Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? . Neurourol Urodyn . 2005;24:231–236
  17. Werner M , Schmid DM , Schussler B . Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study . Am J Obstet Gynecol . 2005;192:1735–1740
  18. Kuo HC . Clinical effects of suburothelial injection of botulinum A toxin in patients with non-neurogenic detrusor overactivity refractory to anticholinergics . Urology . 2005;66:94–98
  19. Schulte-Baukloh H , Weiss C , Stolze T , Sturzebecher B , Knispel HH . Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction . Urology . 2005;66:82–87
  20. Schulte-Baukloh H , Weiss C , Stolze T , et al.   Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction . Eur Urol . 2005;48:984–990
  21. Ghei M , Maraj BH , Miller R , et al.   Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial . J Urol . 2005;174:1873–1877
  22. Rajkumar GN , Small DR , Mustafa AW , Conn G . A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity . BJU Int . 2005;96:848–852
  23. Popat R , Apostolidis A , Kalsi V , Gonzales G , Fowler CJ , Dasgupta P . A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin . J Urol . 2005;174:984–989
  24. Kuo HC . Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? . Urology . 2006;68:993–998
  25. Schmid DM , Sauermann P , Werner M , et al.   Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics . J Urol . 2006;176:177–185
  26. Lucioni A , Rapp DE , Gong EM , Fedunok P , Bales GT . Intravesical botulinum type A toxin injection in patients with overactive bladder: trigone versus trigone-sparing injection . Can J Urol . 2006;13:3291–3295
  27. Hoebeke P , Caestecker KD , Walle JV , et al.   The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor . J Urol . 2006;176:328–331
  28. Kalsi V , Apostolidis A , Popat R , Gonzales G , Fowler CJ , Dasgupta P . Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes . Eur Urol . 2006;49:528–535
  29. Hirst GR , Watkins AJ , Guerrero K , et al.   Botulinum toxin B is not an effective treatment of refractory overactive bladder . Urology . 2007;69:69–73
  30. Ghalayini IF , Al-Ghazo MA . Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction . Neurourol Urodyn . 2007;26:531–536
  31. Sahai A , Khan MS , Dasgupta P . Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial . J Urol . 2007;177:2231–2236
  32. Kuo HC . Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity . J Urol . 2007;178:1359–1363
  33. Jeffery S , Fynes M , Lee F , Wang K , Williams L , Morley R . Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity . BJU Int . 2007;100:1302–1306
  34. Karsenty G , Elzayat E , Delapparent T , St-Denis B , Liemileux MC , Corcus J . Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux . J Urol . 2007;177:1011–1014
  35. Kalsi V , Apostolidis A , Gonzales G , Elneil S , Dasgupta P , Fowler CJ . Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity . Eur Urol . 2008;54:181–187
  36. Kuschel S , Werner M , Schmid DM , Faust E , Schuessler B . Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up . Int Urogynecol J Pelvic Floor Dysfunct . 2008;19:905–909
  37. Brubaker L , Richter HE , Visco A , et al.   Refractory idiopathic urge urinary incontinence and botulinum A injection . J Urol . 2008;180:217–222
  38. White WM , Pickens RB , Doggweiller R , Klein FA . Short-term efficacy of botulinum toxin A for refractory overactive bladder in the elderly population . J Urol . 2008;180:2522–2526
  39. Khan S , Kessler TM , Apostolidis A , et al.   What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type A injection . J Urol . 2009;181:1773–1778
  40. Cohen BL , Barboglio P , Rodriguez D , Gousse AE . Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units . Neurourol Urodyn . 2009;28:205–208
  41. Sahai A , Sangster P , Kalsi V , Khan MS , Fowler CJ , Dasgupta P . Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable . BJU Int . 2009;103:630–634
  42. Flynn MK , Amundsen CL , Perevich M , Liu F , Webster GD . Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder . J Urol . 2009;181:2608–2615
  43. Kessler TM , Khan S , Panicker J , Rosen A , Elneil S , Fowler CJ . Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life . Obstet Gynecol . 2009;113:1046–1051
  44. Andersson KE , Chapple CR , Cardozo L , et al.   Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence . Curr Opin Urol . 2009;19:380–394
  45. Apostolidis A , Dasgupta P , Denys P , et al.   Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report . Eur Urol . 2009;55:100–120
  46. Kuo HC . Measurement of detrusor wall thickness in women with overactive bladder by transvaginal and transabdominal sonography . Int Urogynecol J Pelvic Floor Dysfunct . 2009;20:1293–1299
  47. Mehnert U , Boy S , Schmid M , et al.   A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging . World J Urol . 2009;27:397–403
  48. Zermann DH , Ishigooka M , Schubert J , Schmidt RA . Trigonum and bladder base injection of botulinum toxin A (BTX) in patients with severe urgency-frequency-syndrome refractory to conservative medical treatment and electrical stimulation . Neurourol Urodyn . 2001;20:412–413
  49. Mascarenhas F , Cocuzza M , Gomes CM , Leão N . Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients . Neurourol Urodyn . 2008;27:311–314
  50. Shaban AM , Drake MJ . Botulinum toxin treatment for over-active bladder: risk of urinary retention . Curr Urol Rep . 2008;9:445–451

PII: S1016-3190(09)60056-2

doi: 10.1016/S1016-3190(09)60056-2

Tzu Chi Medical Journal
Volume 21, Issue 4 , Pages 277-284 , December 2009

Article Tools